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See related Letter by Gu, http://www.ccforum.com/content/19/1/236, and related research by Zampieri et al., http://ccforum.com/content/19/1/150We appreciate Gu’s [1] interest in our study. We
apologize and agree with his comment about attribut-
ing units to standardized mean difference (SMD).
Nevertheless, similar to the SMD, results in mean dif-
ference (control – nebulized) were unaffected by neb-
ulized antibiotics (2.67 days, 95 % confidence interval
(CI) –2.89, 8.23 for ICU length of stay (LOS); and
0.70 days, 95 % CI −3.40, 4.80 for mechanical ventilation).
However, we strongly disagree with other points raised by
the letter.
First, the study protocol was defined a priori [2]. We
disagree that combining observational studies with inter-
vention studies is reserved only for safety evaluation.
This topic has been discussed in the literature and com-
bining both types of studies was adequate for our aim
[3]. Furthermore, we presented the main results separat-
ing interventional studies from observational studies,
thereby allowing the reader to interpret both analyses
independently.* Correspondence: otavioranzani@yahoo.com.br
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(http://creativecommons.org/publicdomain/zeSecond, both of the studies cited as “case–control
studies” [1] received this denomination in their title
and abstract. However, by reading their methods it
becomes clear that they are actually matched cohort
studies [4, 5]. Indeed, they matched exposed patients
(“nebulized group”) to unexposed patients (“no-nebu-
lized group”). A case–control design starts with the
outcome (case = “clinical success”) and matches them
with controls (“clinical failures”). Therefore, our measure
of effect was correct [5]. For exploration, we report the
analysis for clinical cure using the odds ratio (OR) (Fig. 1).
The results are unchanged.
Third, Kalin’s study was included because it ful-
filled our inclusion/exclusion criteria [2]. Gu’s sug-
gestion to exclude this study based solely on its
effects in heterogeneity could be considered selective
reporting [1].
Our study provided data for further trials aiming to
evaluate the effect of nebulized antibiotics in ventilator-
associated pneumonia (VAP) [2].icle is distributed under the terms of the Creative Commons Attribution
ons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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Fig. 1 Forest plot for clinical cure using odds ratios (OR). P for overall effect = 0.015. CI confidence interval
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CI: Confidence interval; LOS: Length of stay; OR: Odds ratio;
SMD: Standardized mean difference; VAP: Ventilator-associated pneumonia.
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